Regarding safety, the profile of isatuximab is characterized by an increased risk of grade ≥ 3 neutropenia and infections such as pneumonia, effects consistent with the immunomodulatory actions of anti-CD38 antibodies [22,37]. Here, CD38 is linked to Decreased total neutrophil count.